Investigation of the Effect of Phenylboronic Acid on Androgen-Dependent (LNCaP) and Androgen-Independent (PC3) Prostate Cancer Cells via MAP Kinases by 2D and 3D Culture Methods

Author:

Gürgen Duygu Gürsoy1,Güneş Arzu1,Köse Oğuzhan2,Kaplan Arife Ahsen1,Tunalı M. Başak3,Keskin İlknur1

Affiliation:

1. Department of Histology and Embryology, Faculty of Medicine, Istanbul Medipol University

2. Department of Medical Microbiology, Faculty of Medicine, Istanbul Medipol University

3. Department of Veterinary Histology and Embryology, Faculty of Veterinary Medicine, Istanbul University Cerrahpaşa

Abstract

Abstract Background The castration process is able to regress prostate cancer due to its dependence on androgen. After castration, the disease could progress androgen independently. In our study, two prostate cancer cell lines PC3, LNCaP, and normal prostatic epithelial cell line RWPE-1 were used. PBA an essential compound found in nature, was selected as a chemotherapeutic to examine the effects of microtubule-targeted therapy in human prostate cancer. Colchicine, which belongs to the same class of chemotherapeutics, was included in the study as a positive control treatment. The aim of this study examine the cytotoxic effect of PBA on LNCaP, PC-3, and RWPE-1 cells with two different cell culture methods. Methods The IC50 values treated to the cells following the viability analyses were performed for PBA and Colchicine in 2D and 3D culture models. Colony formation, proliferation, and migration analyses were performed on prostate cancer cells, and chemotherapeutics’s effects were compared. Results In both cancer cell lines, 48 hours of PBA treatment inhibited migration greater than Colchicine. Colony formation analysis showed that the 24 hours PBA treatment prevented the formation. In addition, it was determined that PBA caused a decrease in proliferation parameters in both culture models. The MAPK cellular response induced by PBA was examined by immunofluorescence intensity analysis of kinase proteins of the MAPK pathway, where statistically significant differences were observed between the groups. ERK expression ratio varied in two culture methods, chemotherapeutics, and treatment times. In the 2D culture model, 24 hours of PBA treatment caused a decrease in JNK expression in PC3 and LNCaP cells. Both chemotherapeutic treatments resulted in an increase in p38 expression ratio in PC3 spheroids. On the semi-thin sections, the morphological deformation effect of PBA on cancer cells was pronounced. Morphological defects caused by PBA were first visualized in this study at the ultrastructural level. Conclusion Antimitotic chemotherapeutics may trigger different metabolic responses and also divergences in the signaling mechanisms within different cells. PBA has an anticancer effect potential including inhibiting proliferation and migration. The lower toxicity of PBA on RWPE-1 is remarkable for being a potential chemotherapeutic option in future research.

Publisher

Research Square Platform LLC

Reference64 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34. https://doi.org/10.3322/caac.21551.

2. PSA decline is an independent prognostic marker in hormonally treated prostate cancer;Palmberg C;Eur Urol,1999

3. Türk C, Neisius A, Petřík A, Seitz C, Thomas K, Skolarikos A. EAU Guidelines on Urolithiasis 2020. European Association of Urology Guidelines 2020 Edition 2020;presented.

4. Translational models of prostate cancer bone metastasis;Berish RB;Nat Rev Urol,2018

5. Evaluation of thrombolytic potential of three medicinal plants available in Bangladesh, as a potent source of thrombolytic compounds;Ramjan A;Avicenna J Phytomed,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3